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INTRODUCTION
Multiple Sclerosis (MS) is a common,
heterogeneous disorder of the central ner-
vous system (CNS). Its causes and the fac-
tors that contribute to its heterogeneity are
largely unknown. The disease affects
about 0.1 percent ofthe population in tem-
perate climates (approximately 1.4 million
people worldwide) [1]. It is a disease of
young people (median age of onset is
approximately 28 years) but is lifelong and
is often disabling
In multiple sclerosis, the immune sys-
tem attacks the brain's nerve fibers and
strips away the protective myelin sheath
around nerve fibers in the spinal cord and
brain. The resulting lesions make it diffi-
cult for the nerves to transmit messages.
The cause of MS is not known.
Epidemiological findings support both
environmental and genetic hypotheses,
and these forces likely interact to produce
individual disease susceptibility and influ-
ence disease course.
CELL REPLACEMENT AS A
SOLUTION TO MS
A treatment dilemma posed by MS is
how to restore nerve-insulating myelin
after it is destroyed by the body's immune
system. Because this immune response
also induces the death of oligodendro-
cytes, the myelin-making cells in the brain
and spinal cord, spontaneous remyelina-
tion is insufficient. One of the most excit-
ing areas of MS research is the effort to
transplant myelin-making cells into the
central nervous system. These cells may
be able to repair damage to myelin, regen-
erate injured axons and restore nerve sig-
nal conduction. The key to cell replace-
ment therapies is finding the right cells
not an easy task. One promising prospect
is Schwann cells, myelin-making cells
from the peripheral nervous system.
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CAN SCHWANN CELLS
REMYELINATE AXONS OF DAM-
AGED NEURONS?
As a first step towards answering the
above question, a series of careful animal
studies were carried out by the groups of
Dr. T.L. Vollmer (Associate Professor of
Neurology) and Dr. J.D. Kocsis (Professor
of Neurology and Neurobiology) at Yale
University. Two important studies are dis-
cussed here.
Frozen Schwann cells
isolated from humans can remyelinate
rat axon
Sections of sural nerve were removed
from amputated legs of patients with vas-
cular disease or diabetes, and Schwann
cells were isolated and cryopreserved [2].
Suspensions of reconstituted cells were
transplanted into the X-irradiation/ethidi-
um bromide lesioned dorsal columns of
the immunosuppressed Wistar rat. After
three to five weeks ofextensive remyelina-
tion, a typical Schwann cell pattern was
observed in the lesion zone. The dorsal
columns were removed and maintained in
an in vitro recording chamber; the conduc-
tion properties were studied using field
potential and intra-axonal recording tech-
niques. The transplanted dorsal columns
displayed improved conduction velocity
and frequency-response properties, and
action potentials conducted over a greater
distance into the lesion, suggesting that
conduction block was overcome.
This study established that the
Schwann cells from the sural nerve could
be frozen and then used to remyelinate
CNS axons. It further proved that the
Schwann cells are functional when trans-
planted in that they wrap axons, ameliorat-
ing neuronal impulse conduction prob-
lems.
Quantitative morphometric techniques
help assess the extent and pattern of
remyelination produced by transplanti-
ng allogenic Schwann cells into
demyelinated lesions in adult rat spinal
cords
The effects ofdonor age, prior cultur-
ing ofdonor cells, prior lesioning ofdonor
nerves, and host immunosuppression were
evaluated by transplanting suspensions of
30,000 acutely dissociated or cultured
Schwann cells from neonatal, young adult,
or aged adult rat sciatic nerves into X-irra-
diation and ethidium bromide-induced
demyelinated dorsal column lesions.
Three weeks after transplantation, spinal
cords were processed for histological
analysis. Under all Schwann cell trans-
plant protocols, large areas containing
many Schwann cell-like myelinated axon
profiles could be readily observed
throughout most of the lesion length.
Within these "myelin-rich" regions, the
vast majority ofdetectable axons showed a
peripheral-like pattern of myelination.
However, interaxonal spacing also
increased, resulting in densities of myeli-
nated axons that were more similar to
peripheral nerve than intact dorsal
columns. Freshly isolated Schwann cells
remyelinated more axonal length than cul-
tured Schwann cells, and cells from
younger donors remyelinated slightly
more axon length than cells from older
donors, but all Schwann cell transplant
protocols remyelinated tens of thousands
ofmillimeters of axon length and remyeli-
nated axons at similar densities. These
results indicate that Schwann cells pre-
pared under a variety of conditions are
capable ofeliciting remyelination, but that
the density ofremyelinated axons is much
lower than the myelinated axon density in
intact spinal cords.
The above study assessed the effec-
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cells of CNS axons. While the Schwann
cells did remyelinate, the above quantita-
tive evaluation shows that it was not to the
extent of an uninjured CNS axon.
However, the substantial improvement in
the nerve conduction that can be achieved
through Schwann cell replacement would
be a boon to MS patients. The findings of
this study underscore the need for a moni-
toring the effectiveness of the Schwann
cell replacement in future human trials.
SCHWANN CELL REPLACEMENT
IN HUMANS
Phase One clinical trials
The purpose of the Phase One trial is
to determine whether cells found in the
body's peripheral nerves, in this case, the
ankle, can safely repair the damaged cells
in the brain and spinal cord that result in
neurologic disability in patients with mul-
tiple sclerosis and other disorders of
myelin.
Dr. Timothy L. Vollmer and col-
leagues are carrying out a small trial of
Schwann cell transplantation in five peo-
ple with secondary-progressive MS. Dr.
Jeffrey D. Kocsis's laboratory is providing
technical support. Dr. Kocsis's laboratory
has developed highly efficient ways of
harvesting these cells from individuals
who enroll in the study. Schwann cells will
be taken from the sural nerve ofthe partic-
ipants, and transplanted into areas of
myelin damage in the brain.
This trial is being designed to deter-
mine ifthese cells can survive and to make
sure treatment is safe. The procedure will
be attempted one person at a time, and if
there are any problems, the study will be
stopped. If safety and tolerability of this
invasive procedure can be shown, clinical
trials to test its effectiveness will be
planned which involve larger numbers of
people and a well-controlled design.
The first central nervous system trans-
plantation to repair the myelin-forming
cells in MS was carried out on a woman
with MS. The procedure took place on
July 17 and 18 of 2001. In the first 24
hours, the team isolated the Schwann cells
from the sural nerve, which was removed
from the patient's ankle. A neurosurgery
team led by Dr. Dennis Spencer (Professor
and Chairman of Neurosurgery) then per-
formed stereotactic surgery on the patient,
using an magnetic resonance imaging)
machine to very accurately guide a needle
through the frontal lobe and inject the
Schwann cells into a previously identified
MS lesion.
Dr. Vollmer says the patient was then
studied using a number of techniques,
including neuroimaging and functional
assessments for six months. At the end of
that period, the team used a stereotactic
procedure to take a small biopsy to deter-
mine whether the cells survived and
whether they made any myelin.
A 29-year-old man with MS was the
second patient to undergo this procedure.
The surgery took place on March 6 and 7
of2002, in two stages.
Both patients are doing fine. The
experiment holds promise, not only for the
estimated 1.4 million people worldwide
with MS, but also for patients affected by
other demyelinating diseases, such as the
leukodystrophies, a group of hereditary
diseases that strike children in infancy.
The results of these experiments have
not yet been disclosed.
LORENZO'S OIL AND THE
MYELIN PROJECT
Funding research in MS
The replacement therapy attempted at
Yale is funded by the Myelin Project.
The story ofthe Myelin Project begins
with Augusto and Michaela Odone and
their son Lorenzo. In 1984 Lorenzo came116 Jose: Schwann cells and multiple sclerosis
down with adrenoleukodystrophy (ALD),
a rare inherited disease, in which the
myelin sheath is destroyed. Doctors said
that he would lose all his functions and die
within two to three years. Refusing to
accept this grim verdict, the Odones set
out on a mission to find a treatment for
ALD and to save their child (Lorenzo sur-
vived and is now 23 years old). In their
quest for a treatment, the Odones often
clashed with doctors, scientists, and sup-
port groups, who were skeptical that any-
thing could be done aboutALD, much less
by lay people. The Odones haunted med-
ical libraries, reviewed countless animal
experiments, badgered researchers, ques-
tioned top doctors all over the world, and
persisted until a solution came to them in a
moment of inspiration. They commis-
sioned a special type of oil (oleic acid and
erucic acid) from a British firm, which
normalized the accumulation of very long
chain fatty acids in the blood ofALD boys.
This allowed Lorenzo and others to live on
a restricted diet.
In the second chapter of the story, the
Odones founded The Myelin Project in the
hope offinding a way to restore the myelin
sheath, which is destroyed in ALD and a
host ofother myelin diseases, such as mul-
tiple sclerosis.
For the millions affected by MS, the
groundbreaking Schwann cell replacement
therapy attempted by Dr. Vollmer's team at
Yale is acautious step towards abetter life.
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